Our results suggest that efficient therapy or prevention of microangiopathy through inhibition of the erythrocyte-VWF interaction may decrease the rate of microangiopathic complications in various diseases, such as diabetes, HUS and sickle cell disease. The gene discussed is VWF; the disease is hemolytic-uremic syndrome.